Business
CVKD: Acquires Factor XIa Inhibitors…
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires Portfolio of Factor XIa Inhibitors On September 15, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced it had acquired a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals. Included in the acquired assets is frunexian, a Phase 2-ready asset that is being developed as an acute
About this update from Cadrenal Therapeutics, Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:CVKD","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL CVKD RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Acquires Portfolio of Factor XIa Inhibitors","length":43,"tagName":"p"},{"type":"text","content":"On September 15, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced it had acquired a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals. Included in the acquired assets is frunexian, a Phase 2-ready asset that is being developed as an acute anticoagulant therapy for prevention of coagulation where medical devices play a significant role such as in cardiopulmonary bypass and catheter thrombosis. The portfolio also includes EP-7327, an oral Factor XIa inhibitor for the prevention and treatment of major thrombotic conditions.","length":550,"tagName":"p"},{"type":"text","content":"Anticoagulation therapy is utilized for the prevention and treatment of thrombosis without disrupting hemostasis. Current anticoagulants target FXa or thrombin, which are enzymes in the extrinsic pathway of coagulation. However, inhibition of Factor XIa is a new area of focus since epidemiological and animal data support the concept that Factor XIa is essential for thrombosis but not required for hemostasis. Individuals with congenital FXI deficiency do not have an increased risk for spontaneous bleeding, while at the same time these patients are at a lower risk for venous thromboembolism (VTE) and ischemic stroke. Conversely, patients with elevated FXI levels are at a higher risk for VTE and stroke.","length":709,"tagName":"p"},{"type":"text","content":"Frunexian is a small-molecule inhibitor of Factor XIa and is designed for intravenous administration. While there are a number of other FXIa inhibitors in development (as shown in the following table), frunexian is the only one we are aware of that is being developed in the acute care setting.","length":294,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":2034,"height":896,"url":"https://media.zenfs.com/en/scr.zacks.com/ecc5537dc62249078decbd7419d6b69b"},"resized":{"url":"https://s.yimg.co...